Timolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (tim-hht)—a prospective, randomized, double-blind, controlled, cross-over trial

HIGHLIGHTS

• who: Kornelia E. C. Andorfer and colleagues from the Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauss-Allee, Regensburg, Germany have published the research work: TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)u2014A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial, in the Journal: Pharmaceutics 2022, 14, 2335. of 10/03/2020
• what: The aim of this monocentric, prospective, randomized, placebo-controlled, doubleblinded, cross-over (AB/BA design) study was to evaluate the efficacy of the additional use of timolol nasal spray twice a day (daily dosage . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.